Sodium phenylacetate/Sodium benzoate

Description

Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10%, is a sterile, concentrated, aqueous solution containing sodium phenylacetate and sodium benzoate as active ingredients. The solution has a pH range of 6 to 8. Sodium phenylacetate is presented as a crystalline, white to off-white powder with a strong, offensive odor and is soluble in water, with a molecular weight of 158.13 and a molecular formula of C8H7NaO2. Sodium benzoate appears as a white, odorless crystalline powder that is readily soluble in water, with a molecular weight of 144.11 and a molecular formula of C7H5NaO2. Each milliliter of the injection contains 100 mg of sodium phenylacetate and 100 mg of sodium benzoate, along with Water for Injection. Sodium hydroxide and/or hydrochloric acid may be utilized for pH adjustment. This injection is intended for intravenous administration via a central line only after appropriate dilution.

Uses and Indications

Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% is indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.

This drug does not have any reported teratogenic or nonteratogenic effects.

Dosage and Administration

Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% must be diluted with sterile 10% Dextrose Injection (D10W) prior to administration. It is essential that this medication is administered through a central venous catheter, as administration via a peripheral line may result in burns.

The initial loading dose should be infused intravenously over a period of 90 to 120 minutes. Following the loading dose, an equivalent maintenance dose should be administered as a continuous infusion over a duration of 24 hours. Careful monitoring of the infusion site and patient response is recommended throughout the administration process.

Contraindications

There are no contraindications associated with the use of this product. It is not classified as a controlled substance, and there are no identified risks of abuse, misuse, or dependence. Therefore, the product can be used without specific restrictions related to contraindications.

Warnings and Precautions

Management of acute hyperammonemia requires vigilant monitoring of plasma ammonia levels throughout treatment. Prolonged exposure to elevated plasma ammonia can lead to severe neurological injury or death. Therefore, it is imperative to initiate all necessary therapies promptly to reduce plasma ammonia levels.

Careful monitoring of plasma potassium levels is essential, as decreased potassium levels may occur. Appropriate interventions should be implemented when necessary to address any imbalances.

Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10%, contains 30.5 mg of sodium per mL of the undiluted product. Caution is advised when administering this injection to patients with congestive heart failure, severe renal insufficiency, or any conditions associated with sodium retention and edema, due to the risk of fluid overload.

Extravasation of Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10%, into perivenous tissues during high flow bolus infusion poses a risk of skin necrosis, particularly in infants. It is crucial to closely monitor the infusion site for signs of tissue infiltration during drug administration.

The neurotoxicity associated with phenylacetate necessitates careful consideration of dosing. Due to the prolonged plasma levels observed in pharmacokinetic studies, repeat loading doses should be avoided. Additionally, neurotoxicity related to phenylacetate has been documented in cancer patients; therefore, monitoring for symptoms of acute neurotoxicity is essential.

Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% may induce side effects commonly linked to salicylate overdose, including hyperventilation and metabolic acidosis. Regular monitoring of the patient's blood chemistry profiles is recommended, along with frequent assessments of blood pH and pCO2 levels to ensure patient safety.

Side Effects

Most frequently reported adverse reactions associated with Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10%, occurring in 6% or more of patients include vomiting, hyperglycemia, hypokalemia, convulsions, and mental impairment.

Serious adverse reactions may arise from prolonged exposure to elevated plasma ammonia levels, which can lead to rapid brain injury or death. Therefore, management of acute hyperammonemia is critical. Plasma potassium levels should be carefully monitored, and appropriate treatment should be administered when necessary to address decreased potassium levels.

Caution is advised when administering Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% to patients with congestive heart failure, severe renal insufficiency, or conditions associated with sodium retention and edema, as these may lead to fluid overload. Additionally, extravasation of the injection into perivenous tissues during high flow bolus infusion may result in skin necrosis, particularly in infants.

Neurotoxicity related to phenylacetate has been reported in cancer patients, necessitating close monitoring for symptoms of acute neurotoxicity. The injection may also induce side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis.

Overdosage has been documented in urea cycle-deficient patients receiving Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10%. Causes of death in these cases included cardiorespiratory failure or arrest, hyperammonemia, increased intracranial pressure, pneumonitis with septic shock and coagulopathy, errors in dialysis procedures, respiratory failure, intractable hypotension with probable sepsis, and unknown causes. Signs of intoxication may manifest as obtundation (in the absence of hyperammonemia), hyperventilation, severe compensated metabolic acidosis, large anion gap, hypernatremia, hyperosmolarity, progressive encephalopathy, cardiovascular collapse, and death.

Drug Interactions

Some antibiotics, particularly penicillin, may influence the overall disposition of the infused drug, potentially altering its therapeutic effectiveness.

Probenecid has been shown to impact the renal excretion of phenylacetylglutamine and hippurate, which may necessitate monitoring of these metabolites in patients receiving both agents.

In patients with urea cycle disorders, the administration of valproic acid may exacerbate their condition. This is due to valproic acid's potential to antagonize the efficacy of Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10%, by inhibiting the synthesis of N-acetylglutamate, a critical co-factor for carbamyl phosphate synthetase. Close monitoring of ammonia levels and clinical status is advised in these patients.

Corticosteroids may lead to the breakdown of body protein, which can result in increased plasma ammonia levels, particularly in individuals with a compromised ability to form urea. It is recommended that patients receiving corticosteroids be monitored for signs of hyperammonemia and that dosage adjustments be considered based on clinical assessment.

Packaging & NDC

The table below lists all NDC Code configurations of Sodium Phenylacetate and Sodium Benzoate, the U.S. brand-name prescription product. Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10%, has been utilized for the treatment of acute hyperammonemia in pediatric patients, including those in the early neonatal period. Clinical experience supports its use in this population, although specific dosage adjustments may be necessary based on the age and clinical condition of the patient. Healthcare professionals should exercise caution and closely monitor these patients due to the potential for varying responses and the need for individualized treatment plans.

Geriatric Use

Clinical studies of Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10%, did not include any patients aged 65 and older; therefore, it is unclear whether elderly patients respond differently from younger patients. Additionally, no pharmacokinetic studies have been conducted specifically in geriatric patients.

In general, dose selection for elderly patients should be approached with caution. It is advisable to start at the low end of the dosing range, taking into account the increased likelihood of decreased hepatic, renal, or cardiac function, as well as the presence of concomitant diseases or other drug therapies in this population. Careful monitoring is recommended to ensure safety and efficacy in geriatric patients receiving this treatment.

Pregnancy

Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% is classified as Pregnancy Category C. Animal reproduction studies have not been conducted with this formulation, and there is insufficient data to determine whether it can cause fetal harm or affect reproductive capacity when administered to pregnant patients. Therefore, Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% should be administered to pregnant women only if the potential benefits justify the potential risks to the fetus. Healthcare professionals are advised to carefully consider the necessity of this treatment in pregnant patients.

Lactation

It is not known whether sodium phenylacetate, sodium benzoate, or their conjugation products are excreted in human milk.

Due to the potential for many drugs to be excreted in human milk, caution should be exercised when administering Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% to lactating mothers.

Renal Impairment

Caution should be exercised when administering Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% to patients with severe renal insufficiency. Monitoring of renal function is recommended in this population to ensure safety and efficacy. Dosing adjustments may be necessary based on the degree of renal impairment.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

Overdosage has been documented in patients receiving Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10%, particularly among those with urea cycle disorders. In an uncontrolled open-label study, all participants were intended to receive a uniform dosage of the injection; however, deviations occurred, resulting in some patients receiving doses exceeding the protocol specifications.

In a review of clinical outcomes, it was noted that 16 out of 64 fatalities were associated with a confirmed overdose of Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10%. The causes of death in these cases were varied and included cardiorespiratory failure or arrest (6 patients), hyperammonemia (3 patients), increased intracranial pressure (2 patients), and other complications such as pneumonitis with septic shock and coagulopathy (1 patient), error in dialysis procedure (1 patient), respiratory failure (1 patient), intractable hypotension with probable sepsis (1 patient), and one case with an unknown cause.

Signs of intoxication may manifest as obtundation (notably in the absence of hyperammonemia), hyperventilation, severe compensated metabolic acidosis potentially accompanied by a respiratory component, large anion gap, hypernatremia, hyperosmolarity, progressive encephalopathy, cardiovascular collapse, and ultimately, death.

In the event of an overdose of Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10%, it is imperative to discontinue the medication immediately. Appropriate emergency medical monitoring and interventions should be initiated. In severe cases, the preferred treatment is hemodialysis; however, peritoneal dialysis may be considered if hemodialysis is not available.

Nonclinical Toxicology

Pregnancy Category C indicates that animal reproduction studies have not been conducted with Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10%. The potential for fetal harm when administered to a pregnant woman or effects on reproductive capacity remain unknown. Therefore, Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% should be administered to pregnant women only if clearly needed.

Long-term studies in animals have not been performed to assess the carcinogenic potential of Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10%. Additionally, studies evaluating the possible impairment of fertility or mutagenic potential have not been conducted. However, results indicate that sodium benzoate is not mutagenic or carcinogenic and does not impair fertility.

In animal studies, subcutaneous administration of phenylacetate to rat pups at doses ranging from 190 to 474 mg/kg resulted in decreased neuronal proliferation, increased loss of neurons, and reduced central nervous system (CNS) myelin. Maturation of cerebral synapses was delayed, and the number of functioning nerve terminals in the cerebrum was diminished, leading to impaired brain growth. Pregnant rats received phenylacetate at a dose of 3.5 µmol/g/day subcutaneously from gestation day 7 until normal delivery. Prenatal exposure to phenylacetate in rat pups resulted in lesions in layer 5 cortical pyramidal cells, characterized by longer and thinner dendritic spines than normal, as well as a reduced number of these spines.

Postmarketing Experience

Postmarketing experience has identified several adverse reactions reported voluntarily or through surveillance programs. The most frequently observed adverse reactions include vomiting, hyperglycemia, hypokalemia, convulsions, and mental impairment. These events have been documented in the context of postmarketing surveillance, contributing to the overall understanding of the product's safety profile.

Patient Counseling

Healthcare providers should advise patients and caregivers regarding the safe use of Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10%. It is important to inform patients that once plasma ammonia levels have normalized, they may typically increase dietary protein intake with the aim of achieving unrestricted protein consumption.

Providers should exercise caution when administering Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% to nursing women, as the effects on breastfeeding are not fully established.

Patients should be made aware of the most common adverse reactions associated with this treatment, which include vomiting, hyperglycemia, hypokalemia, convulsions, and mental impairment.

Additionally, it is essential to communicate that BUPHENYL is generally discontinued during the administration of Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10%. This information is crucial for ensuring patient safety and optimizing treatment outcomes.

Storage and Handling

Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10% is supplied in a single-dose glass vial. It should be stored at a temperature of 25°C (77°F), with permissible excursions between 15° and 30°C (59° and 86°F). Care should be taken to ensure that the storage conditions remain within these specified temperature ranges to maintain the integrity of the product.

Additional Clinical Information

Ongoing monitoring of plasma ammonia levels, neurological status, laboratory tests, and clinical response is essential for patients receiving Sodium Phenylacetate and Sodium Benzoate Injection, 10%/10%. Clinicians should also assess blood chemistry profiles, blood pH, and pCO to evaluate patient response to treatment.

Administration of the injection must occur through a central line, as peripheral administration may lead to burns. Bolus infusion flow rates are particularly high for infants, and the product should not be administered undiluted. In cases of suspected extravasation, the infusion should be discontinued and resumed at a different site, with close monitoring for infiltration. Postmarketing experience has indicated that neurotoxicity can occur in cancer patients receiving high doses of intravenous phenylacetate, with symptoms such as somnolence, fatigue, and lightheadedness, which are typically reversible upon discontinuation of the drug.

FDA Insert (PDF)

This document is the official FDA-approved prescribing information for Sodium Phenylacetate and Sodium Benzoate as submitted by Omnivium Pharmaceuticals LLC. It includes detailed information about indications, dosage, contraindications, warnings, and clinical pharmacology.

View full prescribing information (PDF)